The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
|Videos|August 24, 2020
Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial
Advertisement
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
3
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
4
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
5